Bluejay Diagnostics IncBJDX
Price$0.85

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$7.3MTTM through 30 Jun 2026
Free Cash Flow -$6.3MTTM through 30 Jun 2026

Margins

Current

Returns

-113.8%ROE
-95.5%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio4.88x
Net Debt-$5.2Mnet cash position
Cash & Equivalents$9.6M

Quality Metrics

Altman Z-Score-6.57
Piotroski F-Score3 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'22
FY2022: $249K
Diluted EPS-$2.27TTM
'21'22'23'24'25
FY2025: $-15.25

Dividend

No dividend

Capital Allocation

R&D Spend$3.6M

Segment Performance

SegmentRevenueYoYOutlook
Symphony Platform Development$0
View details

The company's operations consist solely of the development of its Symphony diagnostic platform, representing a single reportable segment.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.